A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
Launched by SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. · Mar 20, 2025
Trial Information
Current as of April 23, 2025
Recruiting
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. The age of signing the informed consent is 18 -70 years, regardless of gender.
- • 2. At least one measurable lesion according to RECIST v1.1 criteria.
- • 3. The ECOG score is 0 or 1.
- • 4. Expected survival ≥12 weeks.
- • 5. Good level of organ function.
- • 6. Have the ability to give informed consent and to comply with the treatment plan.
- • 7. Male subjects whose partners are women of childbearing age and female subjects who are fertile are required to use highly effective contraceptive methods.
- Exclusion Criteria:
- • 1. Inadequately treated central nervous system metastases or the presence of uncontrolled or symptomatic active central nervous system metastases.
- • 2. Spinal cord compression not cured by surgery and/or radiotherapy.
- • 3. Subjects with uncontrolled tumor-related pain.
- • 4. Received antitumor therapy within 4 weeks before the start of the study.
- • 5. Subjects with severe cardiovascular and cerebrovascular disease.
- • 6. History of immunodeficiency, including a positive HIV test.
About Shanghai Hengrui Pharmaceutical Co., Ltd.
Shanghai Hengrui Pharmaceutical Co., Ltd. is a leading global pharmaceutical company based in China, recognized for its commitment to innovative research and development in the fields of oncology, anesthesiology, and imaging. Established in 1993, Hengrui has rapidly advanced its portfolio of drug candidates, focusing on both small molecules and biologics to address unmet medical needs. The company emphasizes quality and compliance in its manufacturing processes and is dedicated to enhancing patient outcomes through the development of novel therapeutics. With a strong presence in international markets, Hengrui actively engages in clinical trials to bring cutting-edge treatments to patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Taiyuan, Shanxi, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported